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bstract
ntroduction: Moxibustion is widely used in China and other East Asian countries to manage the symptom of rheumatoid arthritis (RA) and to
essen the adverse effects of western medicine. The purpose of this systematic review was to evaluate the available evidence from randomized
ontrolled trials (RCTs) of moxibustion for treating patients with rheumatoid arthritis (RA).
ethods: Seven Chinese and English databases were searched to November 2013 from their inception. Eligible RCTs were included if moxibustion
as used either alone or in combination with Western medicine for treating rheumatoid arthritis. Study selection, data extraction, and validation
as performed independently by two reviewers. Cochrane criteria for risk of bias was used to assess the methodological quality of the trials.
esults: Eight RCTs met the inclusion criteria, and most were of low methodological quality. Meta-analysis showed favorable effects of moxibustion
n the response rate, either alone [RR = 1.18, 95%CI (1.03, 1.35), p = 0.02; heterogeneity: Chi2 = 1.11, p = 0.77, I2 = 0%] or the combination with
estern medicine therapy [RR = 1.28, 95%CI (1.12, 1.47), p = 0.0004; heterogeneity: Chi2 = 1.96, p = 0.58, I2 = 0%]. When compared with Western
edicine therapy, Western medicine plus moxibustion therapy showed a favorable statistically significant effect on a reduction on American College
f Rheumatology (ACR) 50 [RR = 1.57, 95%CI (1.25, 1.99), p = 0.0001; heterogeneity: Chi2 = 2.87, p = 0.58, I2 = 0%], whereas it failed to do so on
merican College of Rheumatology (ACR) 20. Additionally, when compared with western medicine therapy alone, meta-analysis of three RCTs
uggested favorable but no statistically significant effects of moxibustion plus western medicine on the control of disease activities of rheumatoid
rthritis.
onclusions: It is difficult to draw firm conclusions on whether moxibustion is an effective intervention for treating RA due to the small sample size
f eligible RCTs and the high risk of bias among the available RCTs. Further rigorous RCTs are warranted but need to overcome methodological
hortcomings of the existing evidence.
2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Rheumatoid arthritis (RA) is a chronic systemic inflam-
atory disorder of unknown etiology affecting approximately.2–1% of the world’s population [1–3]. It can be the
onsequence of a pathological process characterized by syno-
ial inflammation and hyperplasia, autoantibody production,
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876-3820/© 2014 Elsevier GmbH. This is an open access article under the CC BY-Nartilage and bone destruction, and systemic complications. The
ost common clinical symptoms include symmetrical arthral-
ia, mainly present in the hands and feet, stiffness, joint damage,
nd loss of physical function [2,3]. RA is a global health problem
oth in developed and developing countries and results in sig-
ificant negative effects on quality of health life in terms of the
ersistent pain, fatigue, disability, as well as the heavy economic
urden associated with disease progression [4–12].
Currently, the treatment strategy is to initiate aggressive
herapy soon after diagnosis [2]. Compared with the conven-
ional drug therapy, the European League Against Rheumatism
EULAR) and the American College of Rheumatology
ACR) recommended that the use of biologic agents can be
ighly beneficial for control inflammatory activity and devel-
C-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
6 f Integ
o
t
a
i
m
n
h
i
i
m
d
m
o
b
m
p
t
i
b
P
n
k
o
s
t
w
a
r
t
s
m
w
d
r
e
a
i
M
I
g
s
a
[
D
t
t
B
t
s
w
c
a
S
e
r
w
t
f22 Z.-l. Sun et al. / European Journal o
pment of erosions in many RA patients [13,14]. Sometimes
hese treatment strategies fail or produce only partial responses,
nd the most impressive drugs may be too expensive for clients
n developing countries [3]. Hence, RA is still a dilemma in
odern medicine.
Moxibustion is an important integral part of traditional Chi-
ese medicine (TCM). It is described as a technique that applies
eat which is generated by burning herbal preparations contain-
ng Artemisia vulgaris to stimulate acupuncture points [15]. It
s generally classified into direct and indirect moxibustion. A
oxa cone placed on the acupuncture point and ignited is called
irect moxibustion. Traditionally it is subdivided into no scarring
oxibustion, and scarring moxibustion according to the degree
f burning over the skin. In the former, the moxa cone is replaced
y a new one when the patient feels a warming sensation. The
oxibustion on an acupuncture point requires repetition of this
rocess 3–7 times. In the latter, the moxa cone is burned on
he skin until blisters are formed. In indirect moxibustion, some
nsulating materials (ginger, salts, herbal cake, etc.) are placed
etween the moxa cone and the skin. Historically, the Spiritual
ivot (Ling Shu, Guan Neng Pian) says: “When needling does
ot work, moxibustion may be appropriate.”
In comparison to acupuncture, moxibustion is less well
nown in western countries, which is due in part to the lack
f the modern medical evidence. Recently, a bibliometric analy-
is of papers published from 1954 to 2007 in China, showed
hat 364 kinds of diseases, including rheumatoid arthritis,
ere being treated with moxibustion [16]. Various system-
tic reviews have investigated the effects of moxibustion on
heumatic conditions [17], osteoarthritis [18], and pain condi-
ions [19]. Nevertheless, there have been no systematic reviews
pecifically focusing on the moxibustion treatment of RA. As
oxibustion originated in China, it was likely that more studies
ould be carried out in China and therefore in more Chinese
atabases were included in the searched compared to previous
eviews.
The aim of this study is to update and critically evaluate the
fficacy and safety of moxibustion in treating RA. This was
chieved by a systematic review and meta-analysis of random-
zed controlled trials (RCTs) that involve moxibustion.
aterials and methods
This study was conducted following the Preferred Reporting
tems for Systematic Reviews and Meta-analyses (PRISMA)
uidelines using a pre-specified protocol, including the search
trategy, inclusion criteria for the articles and methods for the
nalysis, which was developed prior to the beginning of the study
20].
ata sources
Databases searched included; Medline, Embase, CINAHL,
he Cochrane Central Register of Controlled Trials and
hree Chinese databases [WanFang Med Database, Chinese
ioMedical Database, China National Knowledge Infrastruc-
ure (CNKI)] from their inception to November 2013. Search
w
t
t
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trategies are shown in Appendix A, and these search terms
ere slightly modified for other databases. Finally, review arti-
les were searched, and, lists of selected articles were screened
nd checked for potential eligible studies.
elections of studies
Only randomized controlled trials (RCTs) related to the
ffects of moxibustion on RA were included in this systematic
eview. Trials published in the form of dissertations and abstracts
ere also selected as eligible studies. Further, these studies had
o meet the following inclusion criteria:
P (population): patients aged over 18 with rheumatoid arthritis
in any joint.
I (intervention): Studies that compared moxibustion with west-
ern medicine or moxibustion plus western medicine with
western medicine alone. Studies in which moxibustion was
part of a complex intervention were excluded as were studies
where other traditional Chinese therapies (e.g. acupuncture,
Chinese herbals, Chinese patent medicine) were used as an
adjunct treatment in conjunction with moxibustion.
C (comparison): The western medical interventions were con-
firmed as reference standard therapies for RA in the control
group. Studies were excluded if the control group treatments
were not relevant to the western medical therapies, or the
other traditional Chinese therapies (e.g. acupuncture, Chinese
herbals, Chinese patent medicine) were used as an adjunct
treatment in conjunction with the western medical therapies.
O (outcomes): The primary outcome included in this review
was the efficacy of response of RA to treatment with mox-
ibustion by the American College of Rheumatology (ACR)
outcome measures ACR20, 50 and 70, which includes a count
of tender and swollen joints, patient assessment of global pain,
physician assessment of disease activity, a health assessment
questionnaire (HAQ) and laboratory parameters (erythrocyte
sedimentation rate or C-reactive protein) [21]. The ACR meas-
ures have been successfully applied in other meta-analyses
[22]. In addition, the total response rate which is mostly based
on the guiding principles of clinical research on new drugs
of traditional Chinese medicine was also a primary outcome
in this review. Similar to ACR rate, response rate include a
count of tender and swollen joints, morning stiffness dura-
tion, mean grip strength, patient assessment of global pain
and laboratory parameters (erythrocyte sedimentation rate,
C-reactive protein and rheumatoid factor). The secondary out-
come included Disease Activity Score-28 (DAS28), which
is a useful tool for monitoring RA patients. Stable low val-
ues for the DAS28 can indicate uncomplicated course of
RA [23].
Finally, studies with designs that compared two different
orms of moxibustion or different sessions of moxibustion
ere excluded. Trials testing warm needle moxibustion on the
op of acupuncture needle were also excluded because this
ype of intervention cannot evaluate the effects of moxibustion
lone.
f Integrative Medicine 6 (2014) 621–630 623
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ata extraction, quality and validation
All included articles were obtained and read in full. Two
ndependent reviewers (Xu and Sun) extracted the data accord-
ng to predetermined criteria. The Cochrane risk of bias tool was
sed to assess methodological quality of the trials [24]. The fol-
owing characteristics were assessed: (i) selection bias (random
equence generation and allocation concealment), (ii) perfor-
ance bias (patients and participant blinding), (iii) detection
ias (assessor blinding), (iv) attrition bias (incomplete outcome
ata), and (v) reporting bias (selective outcome reporting). As it
s virtually impossible to blind the moxibustion therapists from
he treatment, we evaluated patients and participant blinding and
ssessor blinding separately. Our review used ‘Low, Unclear and
igh’ as keys for the judgments. The answer Low indicated a low
isk of bias, Unclear indicated that the risk of bias was uncertain
nd the answer High indicated a high risk of bias. Disagree-
ents were resolved by discussion between the two reviewers.
f consensus could not be reached, the third reviewer (Du) was
onsulted for a final decision.
uantitative data synthesis
In our review, meta-analysis was performed using soft-
are RevMan 5.2 (available from the website for free:
ttp://www.ccims.net/revman/download). We calculated risk
atio (RR) and 95% confidence intervals (CIs) on dichoto-
ous outcomes, while the effect of moxibustion on continuous
utcomes, mean difference (MD) would be applied in this meta-
nalysis. In each meta-analysis, the chi-square and I2 tests were
sed to measure statistical heterogeneity [24]. Given I2 < 50%
nd p > 0.1, a fixed effect model would be applied. The random
ffect model would be used if articles were considered clinically
imilar enough [25]. If a sufficient number of studies (at least 10)
ere available, publication bias would use a funnel plot [26].
esults
rial ﬂow and study characteristics
The literature search of databases generated 300 citations.
e excluded 263 articles on the basis of duplication, title and
bstract, leaving 37 full texts. Of these 37 articles, 29 were
xcluded according to the inclusion criteria, leaving 8 eligible
CTs involving 494 participants for the systematic review. Fig. 1
hows a flowchart of the trial selection process. Seven RCTs
27–34] adopted a two-arm and one [34] adopted a three-arm
arallel group design. All of the RCTs originated in China. Three
rials tested moxibustion alone [32–34]; moxibustion combined
ith western medicine was used in five studies [27–31]. Except
or one trial [32], the duration of the interventions was mostly
months. Key data regarding the 8 included RCTs [27–34]re summarized in Table 1. Acupuncture point selection was
ased on traditional Chinese medicine (TCM) theory for all of
he included RCTs. Five RCTs [27–31] met the ACR efficacy
valuation criteria, whereas the remaining trials [32–34] only
Q
WFig. 1. Flowchart of the trial selection process.
escribed Chinese medicine efficacy evaluation criteria. The
etails of the treatment regimens are summarized in Table 2.
isk of bias
The Cochrane risk of bias was presented in Figs. 2 and 3.
ost trials had a relatively small sample size and a high risk
f bias. Four of the included trials [27–30] reported appropriate
equence generation methods for the randomization, while one
CT [31] used inappropriate methods and the remaining trials
32–34] did not describe the methods of sequence generation.
ne RCT [28] conducted concealment of allocation by sealed
nvelopes, while the remaining trials did not report this infor-
ation. The authors reported that none of the trials employed
atient blinding, and assessor blinding was unclear in all RCTs.
f the 8 included RCTs, four RCTs [27,31,33,34] stated the risk
f bias for participant dropout or withdrawal.uantitative data synthesis
estern medicine vs Western medicine Plus moxibustion
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Table 1
Summary of the randomized controls trials of moxibustion for rheumatoid arthritis.
Subgroup Study
(author/year)
Sample
size
Follow-
up
Intervention group (regimen) Control group (regimen) Main
outcomes
Intergroup
differences
Western
medicine vs
Western
medicine
Sun (2011)
[27]
40 3 months (A) Indirect moxa (1
session = 30 min, once daily,
5 times/week, 1 month, total
3 sessions, n = 20), plus (B).
I
(B)Drug therapy (MTX,
10 mg, 1/week), plus
NSAIDs, (Celecoxib, 200 mg,
1/day) NSAIDs were used
according to patients’
conditions, n = 20
ACR20 rate RR, 0.69 [0.36,
1.31], NS
ACR50 rate RR, 4.26 [1.06,
17.12], p = 0.04
DAS28 MD,
−0.20[−0.50,
0.10]
Plus
moxibustion
Chen (2013)
[28]
40 3 months (A) Indirect moxa (1
session = 30 min, once daily,
5 times/week, 3 months,
n = 20), plus (B).
(B) Drug therapy (MTX,
10 mg, 1/week), plus
NSAIDs, (Loxoprofen
sodium tablet, 60 mg, 1/day)
NSAIDs were used according
to patients’ conditions, n = 20
Response rate RR, 1.27 [0.96,
1.66], NS
ACR50 rate RR, 1.36 [0.85,
2.18], NS
DAS28 rate MD,
−0.77[−1.09,
−0.45]
withdrawal
rate (NSAIDs)
RR, 2.00 [1.12,
3.57], p = 0.02
Huang (2013)
[29]
40 3 months (A) Indirect moxa (1
session = 30 min, once daily,
5 times/week, 3 months,
n = 20), plus (B).
(B)Drug therapy
(Leflunomide tablets, 20 mg,
1/day, plus NSAIDs, NSAIDs
were used according to
patients’ conditions, n = 20
Response rate RR, 1.12 [0.90,
1.38], NS
ACR20 rate RR, 1.15 [0.77,
1.74], NS
ACR50 rate RR, 1.60 [0.63,
4.05], NS
ACR70 rate RR, 4.0 [0.49,
32.72], NS
DAS28 MD,
−0.29[−1.15,
0.57]
Western
medicine vs
Western
medicine
Li (2006) [30] 60 3 months (A) Indirect moxa (1
session = 30 min, 5
days/week, 3 months, n = 30),
plus (B)
(B) Drug therapy (MTX,
10 mg, 1/week plus NSAIDs,
(loxoprofen, 60 mg, 3/day or
meloxicam 15 mg, 1/day)
NSAIDs were used according
to patients’ conditions, n = 30
Response rate RR, 1.39 [1.00,
1.94], NS
ACR50 rate RR, 1.57 [1.01,
2.44], p = 0.04
with drawal
rate (NSAIDs)
RR, 1.73 [1.18,
2.55], p = 0.01
Plus
moxibustion
Liu (2006)
[31]
62 3 months (A) Indirect moxa (1
session = 30 min, once daily,
5 times/week, 3months,
n = 31), plus (B)
(B) Drug therapy (MTX,
10 mg, 1/week plus NSAIDs,
(Loxoprofen sodium tablets,
60 mg, 3/day) NSAIDs were
used according to patients’
conditions, n = 31
Response rate RR, 1.33 [1.04,
1.72], p = 0.03
ACR50 rate RR, 1.39 [1.00,
1.94], NS
withdrawal
rate (NSAIDs)
RR, 1.82 [1.07,
3.10], p = 0.03
Western
medicine vs
moxibustion
Gong (2007)
[32]
65 n.r. (A) Indirect moxa (1
session = n.r., once every 2
days, 30 days, total 6
sessions, n = 33)
(B) Drug therapy (meloxicam
tablets, 75 mg, 1/day, n = 32)
Response rate RR, 1.34 [1.01,
1.77], p = 0.04
Western
medicine vs
moxibustion
Wang (1999)
[33]
93 3 months (A) Indirect moxa (1
session = n.r., once daily or
once every 2 days, 50
times/session, total 1 session.,
n = 64)
(B) Drug therapy
(Penicillamine, 0. 375–0.
75 g/day, n = 29)
Response rate RR, 1.13 [0.92,
1.40], NS
Yang (2007)
[34]
94 3 months (A) Indirect moxa (1
session = n.r., once daily, 50
times/session, total 1 session,
n = 31)
(C) Drug therapy
(Penicillamine, n = 30)
Response rate B vs. C: RR,
1.12 [0.83,
1.51], NS
(B) Smokeless moxa (1
session = n.r., once daily, 50
times/session, total 1 session,
n = 33)
A vs. C: RR,
1.14 [0.85,
1.52], NS
ACR, American College of Rheumatology; DAS28, disease activity score; MD, mean difference; Moxa, moxibustion; MTX, methotrexate; n.r., not reported; NS,
not significant; NSAIDs, non-steroidal anti-inflammatory drugs; RR, risk ratio.
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Table 2
Summary of the treatment points and other information related to the treatments.
Study (author/year) Types of moxibustion Treatment points Acupoints’ rational theory Adverse events
Sun (2011) [27] Aconite
cake-separated moxa
RN 4, ST36 TCM theory: Invigorate the kidney and
nourish the stomach and spleen
n.r.
Chen (2013) [28] Aconite
cake-separated moxa
RN 4, ST36 TCM theory: Invigorate the kidney and
nourish the stomach and spleen
None related to
moxa.
Huang (2013) [29] Aconite
cake-separated moxa
RN 4, ST36 TCM theory: Invigorate the kidney and
nourish the stomach and spleen
n.r.
Li (2006) [30] Aconite
cake-separated moxa
RN 4, ST36 TCM theory: Invigorate the kidney and
nourish the stomach and spleen
None related to
moxa
Liu (2006) [31] Aconite
cake-separated moxa
RN 4, ST36 TCM theory: Invigorate the kidney and
nourish the stomach and spleen
None related to
moxa
Gong (2007) [32] Herbal cake-separated
moxa
DU 13, BL 11, BL 17, BL 20, BL 23 TCM theory: Warm the kidney and
spleen, expel wind and dampness, and
strengthen tendons and bones.
n.r.
Wang (1999) [33] Aconite
cake-separated
moxa
Group 1: RN 17, RN 12, RN 6, RN8,
ST 36
TCM theory: not report in details None related to
moxa.
Group 2: BL17, BL 18, BL 20, DU 4 TCM theory: not report in details
Two group points were used
interchangeably in every treatment.
Yang (2007)
[34]
Ginger
cake-separated
moxa
Group 1: RN 17, RN 12, RN 6, RN8,
ST 36
n.r.
Group 2: BL17, BL 18, BL 20, DU 4
Two group points were used
eatme
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CR, American College of Rheumatology; TCM, traditional Chinese medicine
CR20 rate. There were two RCTs [27,29] (n = 80), which used
CR20 rate as a measure of the effects for improving RA. The
wo studies both showed no statistically significance between
he groups on the ACR20 rate. The meta-analysis suggested
hat, compared with Western medicine therapy, moxibustion plus
estern medicine therapy had no statistically significant favor-
ble effects on the ACR20 rate [RR = 0.94, 95% CI (0.66,1.33),
= 0.72] (Fig. 4)
CR50 rate. There were five RCTs [27–31] (n = 242), which
sed ACR50 rate as a measure of the effects for improving RA.
wo of the studies [27,30] showed statistically significant posi-
ive effects on the ACR50 rate between groups, while the other
hree [28,29,31] did not. The result of meta-analysis suggested
s
e
t
h
Fig. 2. Risk of bias summary: review authors’ judgments ant.
not reported.
hat, compared with Western medicine therapy, moxibustion plus
estern medicine therapy had statistically significant favorable
ffects in improving the ACR50 rate [RR = 1.57, 95% CI (1.25,
.99), p = 0.0001] with low heterogeneity [Chi2 = 2.87, p = 0.58,
2
= 0%] (Fig. 4).
esponse rate. There were four RCTs [28–31] (n = 202), which
sed response rate as an outcome on the effects for improving
A. Only one [31] research indicated significant positive effect
n response rate between groups, but the pooled meta-analysis
howed significantly superior effects of moxibustion plus West-
rn medicine therapy when compared with Western medicine
herapy. [RR = 1.28, 95%CI (1.12, 1.47), p = 0.0004] with low
eterogeneity [Chi2 = 1.96, p = 0.58, I2 = 0%] (Fig. 4).
bout each risk of bias item for each included study.
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Fig. 3. Risk of bias graph: review authors’ judgments about each risk of bias
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more likely to overestimate the results of the outcome meas-
ures [35,36]. For adequate random sequence generation, hightem presented as percentages across all included studies.
AS28. There were three RCTs [27–29] (n = 120), which used
AS28 to measure the disease activity score of the RA. The
esult of meta-analysis showed that, compared with Western
edicine therapy, moxibustion plus Western medicine therapy
ad favorable but not statistically significant effects in improving
A conditions. [MD = −0.45, 95%CI (−0.89, −0.01), p = 0.05]
Fig. 5).
Of the remaining studies, one study [29] (n = 40), which was
ot included in the meta-analysis, used ACR70 rate as a mea-
urement. The moxibustion plus Western medicine therapy on
CR70 rate indicated no statistically significant effect when
ompared with Western medicine therapy. [RR = 4.0, 95%CI
0.49, 32.72), p > 0.05].
r
srative Medicine 6 (2014) 621–630
estern medicine vs moxibustion
esponse rate
Three RCTs (n = 252) tested the effects of moxibustion com-
ared with western medicine therapies in patients with RA. Only
ne RCT [32] suggested that, compared with Western medicine
herapies alone, moxibustion therapy showed favorable statisti-
ally significant results on response rate. The meta-analysis of
he three eligible trials showed significantly positive effects of
oxibustion on response rate. [RR = 1.18, 95%CI (1.03, 1.35),
= 0.02] with high heterogeneity [Chi2 = 1.11,p = 0.77, I2 = 0%]
Fig. 6)
dverse effects
Of included eight trials, four [28,30,31,33] RCTs assessed
dverse effects while the other four [27,29,32,34] RCTs did not.
everal common adverse outcomes (nausea and vomiting, the
isks of liver injury, leucopenia, rash, etc.) from drug therapy
n moxibustion combined with western medical therapies were
eported in these trials [27,29,32,34].
iscussion
Our studies suggested that moxibustion may have beneficial
ffects for treating RA. However, considering the high risks of
ias of all included trials, and the relative small sample size
n each group, these positive results should be interpreted with
aution.
A meta-analysis published in 2011 summarized and critically
valuated the effectiveness of moxibustion for major rheumatic
onditions (including 4 studies on RA) [17]. They found a supe-
ior but limited evidence of impact and effectiveness related to
heumatic conditions. Nevertheless, a subgroup analysis of RA
howed no statistically significant differences in the response
ate of moxibustion versus conventional drug therapy. Moreover,
hen compared with the drug therapy, the subgroup analysis
lso failed to show the favorable effects of moxibustion plus
rug therapy on the response rate. These results from previ-
us reviews [17] seemed to be inconsistent with our systematic
eview. Currently, in our review, more new RCTs published after
010 were also identified and successfully updated the avail-
ble evidence concerning moxibustion therapy. Therefore, it is
mportant to consider that a meta-analysis should be updated
eriodically as new RCTs are published. However, considering
lot of low methodological quality RCTs in our meta-analysis,
e still cannot reverse the results from the previous study in
erms of the available evidence.
We assessed the methodological quality of primary studies
sing the risk of bias assessment tool from the Cochrane Hand-
ook. In this context, most of the included studies in this review
howed the high risk bias in various aspects. First of all, trials
ith inadequate random sequence generation and inadequate
llocation concealment may be subject to selection bias and areisk of bias was given to 50% of the included studies. Though
ome studies claimed to use randomized trials, they failed to
Z.-l. Sun et al. / European Journal of Integrative Medicine 6 (2014) 621–630 627
Fig. 4. Western medicine Plus moxibustion therapy vs Western medicine therapy on ACR20 rate, ACR50 rate and response rate.
Fig. 5. Western medicine Plus moxibustion therapy vs Western medicine therapy on DAS28.
Fig. 6. Moxibustion therapy alone vs Western medicine therapy on response rate.
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escribe in detail the process of randomization. Additionally,
ne RCT [28] reported that participants were assigned to the
ontrol and intervention groups based on the dates they were
dmitted to the hospitals, which should not be considered as ade-
uate randomization. For the allocation concealment, the group
ssignment was adequately concealed in only 12.5% of included
tudies and the rest of the studies were given unclear risk of
ias, mostly due to a lack of related reporting. Therefore, results
f this meta-analysis may seem to be more optimistic than it
hould be. Furthermore, details of drop-outs and withdrawals
ere described in only 50% of included trials. This may lead
o exclusion or attrition bias [37]. Last but not least, due to the
ature of moxibustion interventions, participant blinding was not
lways feasible. However, no single included study mentioned
linding assessors. Hence, selection, performance, attrition and
etection biases were prevalent in most of the included studies.
Having a placebo or sham moxibustion comparable to the
pecific effects of moxibustion may be essential and critical in
he randomized controlled trial. In all included studies, none
ested the different effects between the sham moxibustion and
he specific effects of moxibustion. Hence, one problem with
linical trials of moxibustion is finding a suitable placebo con-
rol. Considering that the possible effects of moxibustion could
ome from stimulating acupuncture points with heat, sham
oxibustion might include treating outside acupuncture points
n non-acupuncture points or preventing heat stimulation on
cupuncture points or areas. Currently, two placebo or sham
oxibustion methods have been proposed for trials of moxibus-
ion, and these could achieve patient and practitioner blinding
38,39]. However, in terms of their reliability, some discrepan-
ies may continue to exist. The main drawback of these sham
oxibustion methods is the lack of the essential characteristics
f the moxibustion, the smoke, smell and the sensation [40].
ecently, a pilot placebo-controlled trial has assessed the effect
f moxibustion treatment with a sham control [41]. Neverthe-
ess, the number of patients was too small to generate reliable
ndings. Therefore, there are no universally accepted placebo or
ham moxibustion devices, and the adequate sham moxibustion
evices may be created in the future.
One argument for using moxibustion for treating RA might
e that it is safer than western medicine [42]. In this study, Four
CTs [27,29,32,34] reported that adverse events (nausea and
omiting, the risks of liver injury, leucopenia, rash, etc.) were
rom drug therapy in moxibustion combined with western medi-
al therapies group. Moxibustion may be a safe treatment for RA
n this study. However, the probable adverse events of moxibus-
ion including allergic reactions, burns and infections have been
eported in previous research [43,44]. Therefore, future trials
hould provide more details about any adverse events associated
ith moxibustion or safety assessment.
Another important issue that should be discussed is the
ulture-specific efficacy evaluation of RA. Subjects in five RCTs
et the ACR criteria [27–31], whereas the remaining studies32–34] only described Chinese medicine assessment. In con-
rast with Korea and Japan, there are many disparities in the
idely published and accepted standardized evaluations of effi-
acy in the field of Complementary and Alternative Medicine
i
m
w
orative Medicine 6 (2014) 621–630
45]. Hence, in addition to Chinese medicine assessment, for
uture studies, it is recommended that trials should use ACR
utcome measures to evaluate the effectiveness of moxibustion
or treating RA.
Assuming that moxibustion is a beneficial treatment for
A, possible mechanisms of action are of interest. In modern
esearch, the widely accepted view of the mechanisms oper-
ting is that of anti-inflammation and immunoregulation theory
46]. Moxibustion can reduce the release of inflammatory media-
ors [interleukin (IL)-1, interleukin (IL)-6, tumor necrosis factor
TNF), etc.], regulate the central neurotransmitter level [nitric
xide (No)], improve the body’s immune function, and protect
he thymus, spleen and other immune organs [46–48]. Another
ypothesis is the thermal stimulation effect theory. Heat stimu-
ated by burning moxa transferred to skin, which is recognized
y the thermal sensory receptors as invasive stimulation. When
his stimulation activates on the thermal sensory receptors, the
ignal enters the central nervous system through nerve fibers,
nd the therapeutic effects can be produced [49]. In a recent
rthritic rat model study, moxibustion seemed to have positive
ffects on the rat’s muscle regeneration by inhibiting the TGF-B1
nd myostatin and activating IGF-1 [50]. None of these theories
re, however, currently fully established. Hence, there is still a
reat distance to go before we fully understand the mechanism
nvolved with moxibustion.
tudy limitations
This review may have several important limitations. First of
ll, this systematic review had a high risk of bias, which seemed
o result in the positive results we found. In the future, in order to
void bias, we suggest that authors refer to the recent extension
f the Consolidated Standards of Reporting Trials (CONSORT)
tatement for trials of moxibustion interventions [51,52]. In
ddition, the sample size of included studies was very small.
urrently, there are no rules regarding sample-size requirements
or a meta-analysis. However, in order to avoid false positive
onclusions due to an insufficient number of patients, the total
umber of patients included in a meta-analysis should be at least
s large as that in a well-designed and optimally powered RCT
53]. Therefore, a larger total number of patients may be needed
n the future studies. Furthermore, a potential source of bias of
his review may originate from the search strategy. The search
trategy utilized is more likely to detect English and Chinese lan-
uage publications. Considering that moxibustion therapy is also
ne of the most widely used basic oriental medical techniques
n Korea and Japan, it is possible that relevant publications have
ot been identified. Hence, more databases should be searched
o identify publications in Korean and Japanese languages other
han English and Chinese. Additionally, due to the number of
ooled studies was too small, it was not suitable for us to formally
est asymmetry in the funnel plot. Moreover, the publication bias
n favor of positive conclusions about moxibustion therapies
ay generate this meta-analysis [54]. Lastly, all include RCTs
ere conducted on Chinese populations; therefore the results are
nly limited to Asian populations. Further studies should include
f Integ
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ifferent populations.
In the future, there is a need for robust, methodologically
ound, randomized controlled trials of adequate statistical power
nd validated outcome measurements to evaluate the efficacy as
ell as safety of moxibustion for RA. Furthermore, if possi-
le, the long-term effects of moxibustion and assessor blinding
hould be taken into the consideration in the future trials.
onclusions
It is difficult to draw firm conclusions that moxibustion is
n effective intervention for treating RA due to the small sam-
le size of eligible RCTs and the high risk of bias among the
vailable RCTs. Further rigorous RCTs are warranted but need
o overcome methodological shortcomings of the existing evi-
ence.
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ppendix A. Search strategies
EDLINE
. arthritis, rheumatoid [mh]
. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or
revmatic or rheumat* or reumat* or revmarthrit*) adj3 (arthrit* or
artrit* or diseas* or condition* or nodule*)) [tw]
. 1 or 2
. Moxibustion [mh]
. moxa [tw]
. 4 or 5
. 3 and 6
. randomized controlled trial [pt]
. controlled clinical trial [pt]
0. randomized [tiab]
1. placebo [tiab]
2. clinical trials as topic [mesh: noexp]
3. randomly [tiab]
4. trial [ti]
5. or/8-14
6. animals [mh] NOT humans [mh]
7. 15 not 16
8. 7 and 17
[rative Medicine 6 (2014) 621–630 629
mbase
. exp arthritis, rheumatoid/
. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or
revmatic or rheumat* or reumat* or revmarthrit*) adj3 (arthrit* or artrit*
or diseas* or condition* or nodule*)).af.
. 1 or 2
. exp Moxibustion/
. moxa .af.
. 4 or 5
. 3 and 6
. (random* OR factorial* OR crossover* OR placebo*).af.
. exp crossover-procedure/or exp double-blind procedure/or exp
randomised controlled trial/or single-blind procedure/
0. 8 or 9
1. 7 and 10
ochrane Central Register of Controlled Trials
1 MeSH descriptor Arthritis, Rheumatoid explode all trees
2 ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or
revmatic or rheumat* or reumat* or revmarthrit*) near/3 (arthrit* or
artrit* or diseas* or condition* or nodule*)):ti,ab
3 (#1 OR #2)
4 MeSH descriptor Moxibustion explode all trees
5 moxa*:ti,ab
6 (#4 OR #5)
7 (#3 AND #6)
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